Union Savings Bank Has $774,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Union Savings Bank decreased its stake in Johnson & Johnson (NYSE:JNJ) by 8.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,353 shares of the company’s stock after selling 498 shares during the period. Union Savings Bank’s holdings in Johnson & Johnson were worth $774,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $31,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson during the third quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in Johnson & Johnson during the third quarter worth $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $145.39 on Thursday. The stock has a 50-day simple moving average of $148.26 and a 200 day simple moving average of $156.12. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market capitalization of $350.04 billion, a price-to-earnings ratio of 21.04, a P/E/G ratio of 2.50 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.29 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 9.95 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.41%. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Barclays decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Bank of America cut their price objective on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a report on Friday, January 17th. Finally, Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $173.27.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.